Fujairah Mountain Shooting Championship Returns for a New Edition in February 2025
9.9.2024 17:44:00 CEST | Business Wire | Press release
The Fujairah Shooting Club announces the important dates, side events, ambassadors and launch of the website of the second edition of Fujairah Mountain Shooting Championship
Following the resounding success of its inaugural edition in 2023, Fujairah Shooting Club has announced the return of the Fujairah Mountain Shooting Championship (FMSC) and the launch of the championship's official website for its second edition. The unparalleled and challenging sporting event will return in February 2025 and will be held under the patronage of His Highness Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah.
The championship, which will run from February 1 to 8, 2025, in Dibba, Fujairah, UAE, will feature challenging layouts, exhilarating side events, and the chance to experience the natural beauty of the Emirate. The main championship, which will be held from February 5 to 8, will feature Super Sporting with 240 clays, a total prize of USD 300,000, and USD 50,000 for 100 flash clays.
The preliminary competitions of FMSC 2025 will be held from February 1 to 4 and will feature 50 clays of English Sporting with a total prize pool of USD 40,000 across four categories. The opening ceremony will be held on February 4, and the awards ceremony is scheduled for February 8, 2025.
The main championship will feature 24 stands, each equipped with six machines and presenting ten targets, including singles and doubles. Over the course of four days, 240 targets will be set, with 60 targets to be covered each day, and participants will be organised into six-man squads to compete throughout the event.
Saif Al Zahmi, Director, FMSC, said: “Held under the patronage of H.H. Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah, FMSC draws inspiration from the rich hunting tradition of the region and celebrate its enduring heritage. We are delighted to announce the launch of the website, kicking off the most anticipated return of the event with many new additions in February 2025. Moreover, it is a unique sporting event with over AED 1,000,000 in prizes and a chance to experience the region's vibrant culture. The competition, along with exciting side events, promises an exhilarating experience while respecting the environment through the use of ammunition with 100% natural biodegradable wads and eco-friendly clay targets suitable for all ages.”
One of the highlights of the 2025 edition is side events such as Pool Shoots and English Sporting, which will be held from February 1 to 7. Additionally, the latest edition of the championship is organised with the support of the National Sporting Clays Association and the Clay Pigeon Shooting Association, features George Digweed MBE, a renowned English sport shooter and multiple world and European clay-shooting champion; Phil Gray and Saif Bin Futtais, an Emirati sport shooter and five-time Olympian, as ambassadors.
For more information, visit fmsc.ae.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909161040/en/
Contacts
Tarek Kamal El Dine, +971 50 8829649
Tarek Kamal El Dine, +971 50 8829649
tarek@cpo.fujairah.ae
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom